Ost-müük Eli Lilly & Co - LLY CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 2.49 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.030779% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | -0.013666% | ||||||||
Ööpäeva tasu aeg | 22:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eli Lilly and Co ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Eelmine sulgemine* | 330.39 |
Avatud* | 329.73 |
Aastane muutus* | 31.38% |
Päeva ulatus* | 329.73 - 341.12 |
52 nädala ulatus | 231.87-384.44 |
Keskmine maht (10 päeva) | 3.98M |
Keskmine maht (3 kuud) | 59.59M |
Turukapitalisatsioon | 322.19B |
P/E suhtarv | 49.13 |
Ringluses olevad aktsiad | 950.18M |
Tulu | 28.54B |
EPS | 6.90 |
Dividendid (% kasumist) | 1.33302 |
Beeta | 0.33 |
Järgmine tuluaruande kuupäev | Apr 27, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
Feb 3, 2023 | 337.93 | 5.58 | 1.68% | 332.35 | 342.09 | 328.30 |
Feb 2, 2023 | 330.39 | -2.41 | -0.72% | 332.80 | 334.80 | 316.14 |
Feb 1, 2023 | 342.15 | 1.23 | 0.36% | 340.92 | 345.40 | 336.80 |
Jan 31, 2023 | 343.91 | 5.17 | 1.53% | 338.74 | 344.11 | 338.74 |
Jan 30, 2023 | 340.18 | -1.86 | -0.54% | 342.04 | 347.28 | 339.15 |
Jan 27, 2023 | 341.77 | -2.99 | -0.87% | 344.76 | 347.70 | 341.32 |
Jan 26, 2023 | 347.65 | -2.14 | -0.61% | 349.79 | 351.79 | 346.30 |
Jan 25, 2023 | 349.26 | 7.35 | 2.15% | 341.91 | 349.50 | 341.91 |
Jan 24, 2023 | 345.92 | -16.82 | -4.64% | 362.74 | 364.89 | 339.80 |
Jan 23, 2023 | 341.82 | -2.04 | -0.59% | 343.86 | 345.86 | 339.80 |
Jan 20, 2023 | 345.80 | 1.01 | 0.29% | 344.79 | 348.73 | 341.12 |
Jan 19, 2023 | 350.82 | 1.39 | 0.40% | 349.43 | 355.30 | 349.43 |
Jan 18, 2023 | 351.45 | -4.05 | -1.14% | 355.50 | 358.73 | 351.25 |
Jan 17, 2023 | 357.38 | -1.09 | -0.30% | 358.47 | 361.50 | 356.17 |
Jan 13, 2023 | 361.23 | 6.08 | 1.71% | 355.15 | 362.95 | 355.15 |
Jan 12, 2023 | 358.72 | 3.25 | 0.91% | 355.47 | 360.15 | 351.69 |
Jan 11, 2023 | 359.86 | 7.67 | 2.18% | 352.19 | 361.49 | 348.71 |
Jan 10, 2023 | 352.54 | 5.75 | 1.66% | 346.79 | 352.96 | 342.22 |
Jan 9, 2023 | 349.45 | -13.34 | -3.68% | 362.79 | 364.60 | 348.43 |
Jan 6, 2023 | 362.71 | 4.92 | 1.38% | 357.79 | 366.20 | 356.41 |
Eli Lilly & Co Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Aastas
- Kvartalis
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Kogutulu | 21222.1 | 19973.8 | 21493.3 | 22319.5 | 24539.8 | 28318.4 |
Tulu | 21222.1 | 19973.8 | 21493.3 | 22319.5 | 24539.8 | 28318.4 |
Kulud, Kokku | 5654.9 | 4447.7 | 4681.7 | 4721.2 | 5483.3 | 7312.8 |
Brutokasum | 15567.2 | 15526.1 | 16811.6 | 17598.3 | 19056.5 | 21005.6 |
Kogu tegevuskulu | 17763.3 | 17970.5 | 17958.8 | 17287.9 | 18481.8 | 22366.5 |
Müük/Üldine/admin kulud, kokku | 6452 | 5982.4 | 5975.1 | 6213.8 | 6121.2 | 6431.6 |
Uuringud ja arendus | 5243.9 | 5096.2 | 5051.2 | 5595 | 6085.7 | 7025.9 |
Ootamatud kulutused (tulu) | 412.5 | 2444.2 | 2250.8 | 757.9 | 791.6 | 1596.2 |
Tulud majandustegevusest | 3458.8 | 2003.3 | 3534.5 | 5031.6 | 6058 | 5951.9 |
Intressitulud (kulu), muud tulud, neto | -76.5 | -58.6 | -83.2 | -320.2 | -326.6 | -137.5 |
Muud, neto | -8.3 | 360.1 | 228.8 | 554.5 | 1498.5 | 341.1 |
Netotulu enne makse | 3374 | 2304.8 | 3680.1 | 5265.9 | 7229.9 | 6155.5 |
Netotulu pärast makse | 2737.6 | 4493.6 | 3325.9 | 4637.9 | 6193.7 | 5581.7 |
Netotulu enne erikulusid | 2737.6 | 4493.6 | 3325.9 | 4637.9 | 6193.7 | 5581.7 |
Netotulu | 2737.6 | -204.1 | 3232 | 8318.4 | 6193.7 | 5581.7 |
Arvestatav tulu, v a erikulud | 2737.6 | 4493.6 | 3325.9 | 4637.9 | 6193.7 | 5581.7 |
Arvestatav tulu, koos erikuludega | 2737.6 | -204.1 | 3232 | 8318.4 | 6193.7 | 5581.7 |
Jaotamisele kuuluv netotulu | 2737.6 | -204.1 | 3232 | 8318.4 | 6193.7 | 5581.7 |
Keskmine jaotamisele kuuluv aktsia kohta | 1061.82 | 1052.02 | 1033.67 | 935.684 | 912.505 | 911.681 |
Jaotatav EPS, v a erakorralised kulud | 2.5782 | 4.27139 | 3.21757 | 4.95669 | 6.78758 | 6.12243 |
Dividends per Share - Common Stock Primary Issue | 2.04 | 2.08 | 2.25 | 2.58 | 2.96 | 3.4 |
Jaotamisele kuuluv normaal-EPS | 2.89874 | 6.15171 | 5.37021 | 5.70063 | 7.63447 | 7.79951 |
Erakorralised kulud kokku | -4697.7 | -93.9 | 3680.5 | 0 | 0 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Kogutulu | 6805.6 | 6740.1 | 6772.8 | 7999.9 | 7810 |
Tulu | 6805.6 | 6740.1 | 6772.8 | 7999.9 | 7810 |
Kulud, Kokku | 1878.6 | 1953.2 | 1430.8 | 2050.2 | 2072.1 |
Brutokasum | 4927 | 4786.9 | 5342 | 5949.7 | 5737.9 |
Kogu tegevuskulu | 5650.3 | 5336.7 | 5296.8 | 6082.7 | 5405.7 |
Müük/Üldine/admin kulud, kokku | 1576 | 1685.7 | 1577.9 | 1592 | 1557.9 |
Uuringud ja arendus | 1684.8 | 1672.8 | 1708.9 | 1959.4 | 1610.1 |
Ootamatud kulutused (tulu) | 510.9 | 25 | 579.2 | 481.1 | 165.6 |
Tulud majandustegevusest | 1155.3 | 1403.4 | 1476 | 1917.2 | 2404.3 |
Intressitulud (kulu), muud tulud, neto | 219.2 | 133.9 | -323.4 | -167.2 | -503.3 |
Muud, neto | 101.9 | 56.6 | 92.7 | 89.9 | 152.6 |
Netotulu enne makse | 1476.4 | 1593.9 | 1245.3 | 1839.9 | 2053.6 |
Netotulu pärast makse | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Netotulu enne erikulusid | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Netotulu | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Arvestatav tulu, v a erikulud | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Arvestatav tulu, koos erikuludega | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Jaotamisele kuuluv netotulu | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Keskmine jaotamisele kuuluv aktsia kohta | 912.4 | 910.4 | 910.8 | 911.624 | 906.4 |
Jaotatav EPS, v a erakorralised kulud | 1.48542 | 1.52702 | 1.21882 | 1.89343 | 2.0994 |
Dividends per Share - Common Stock Primary Issue | 0.85 | 0.85 | 0.85 | 0.85 | 0.98 |
Jaotamisele kuuluv normaal-EPS | 2.02635 | 1.55448 | 1.80644 | 2.41408 | 2.28211 |
Erakorralised kulud kokku | 0 |
- Aastas
- Kvartalis
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Käibevarad kokku | 15101.4 | 19202.1 | 20549.6 | 13709.6 | 17462.1 | 18452.4 |
Raha ja lühiajalised investeeringud | 6038.6 | 8034.1 | 7408.9 | 2438.5 | 3681.3 | 3908.6 |
Raha ja ekvivalendid | 4582.1 | 6536.2 | 7320.7 | 2337.5 | 3657.1 | 3818.5 |
Lühiajalised investeeringud | 1456.5 | 1497.9 | 88.2 | 101 | 24.2 | 90.1 |
Laekumata arved, neto | 4766.3 | 5262.2 | 5776.8 | 5541.5 | 6929 | 8127.2 |
Accounts Receivable - Trade, Net | 4029.4 | 4546.3 | 5776.8 | 4547.3 | 5875.3 | 6672.8 |
Total Inventory | 3561.9 | 4458.3 | 3098.1 | 3190.7 | 3980.3 | 3886 |
Prepaid Expenses | 734.6 | 1447.5 | 2036.7 | 2538.9 | 2871.5 | 2530.6 |
Total Assets | 38805.9 | 44981 | 43908.4 | 39286.1 | 46633.1 | 48806 |
Property/Plant/Equipment, Total - Net | 8252.6 | 8826.5 | 7996.1 | 8405 | 8681.9 | 8985.1 |
Property/Plant/Equipment, Total - Gross | 16777.6 | 18091.1 | 16663 | 17566.6 | 18252.6 | 18961.8 |
Accumulated Depreciation, Total | -8525 | -9264.6 | -8666.9 | -9161.6 | -9570.7 | -9976.7 |
Goodwill, Net | 3972.7 | 4370.1 | 1366.6 | 3679.4 | 3766.5 | 3892 |
Intangibles, Net | 4357.9 | 4029.2 | 1068 | 6618 | 7450 | 7691.9 |
Long Term Investments | 5207.5 | 5678.8 | 2005.4 | 1962.4 | 2966.8 | 3212.6 |
Other Long Term Assets, Total | 1913.8 | 2874.3 | 10922.7 | 4911.7 | 6305.8 | 6572 |
Total Current Liabilities | 10986.6 | 14535.9 | 11888.1 | 11775.2 | 12481.6 | 15052.7 |
Accounts Payable | 1349.3 | 1410.7 | 1207.1 | 1405.3 | 1606.7 | 1670.6 |
Accrued Expenses | 896.9 | 997.9 | 955.6 | 915.5 | 997.2 | 958.1 |
Notes Payable/Short Term Debt | 1299.3 | 2696.8 | 498.9 | 1494.2 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 638.1 | 1009.8 | 603.3 | 5.1 | 8.7 | 1538.3 |
Other Current Liabilities, Total | 6803 | 8420.7 | 8623.2 | 7955.1 | 9869 | 10885.7 |
Total Liabilities | 24798.2 | 33388.8 | 34079.7 | 36679.2 | 40991.5 | 39826.8 |
Total Long Term Debt | 8367.8 | 9940.5 | 9196.4 | 13817.9 | 16586.6 | 15346.4 |
Long Term Debt | 8358.8 | 9931.8 | 9196.4 | 13817.9 | 16586.6 | 15346.4 |
Capital Lease Obligations | 9 | 8.7 | ||||
Minority Interest | 72.8 | 75.7 | 1080.4 | 92.2 | 183.6 | 175.6 |
Other Liabilities, Total | 5371 | 8836.7 | 10602.1 | 8806.4 | 9639.8 | 7518.4 |
Total Equity | 14007.7 | 11592.2 | 9828.7 | 2606.9 | 5641.6 | 8979.2 |
Common Stock | 688.5 | 687.9 | 661 | 598.8 | 598.2 | 596.3 |
Additional Paid-In Capital | 5640.6 | 5817.8 | 6583.6 | 6685.3 | 6778.5 | 6833.4 |
Retained Earnings (Accumulated Deficit) | 16046.3 | 13894.1 | 11395.9 | 4920.4 | 7830.2 | 8958.5 |
Treasury Stock - Common | -80.5 | -75.8 | -69.4 | -60.8 | -55.7 | -52.7 |
Unrealized Gain (Loss) | 224 | 113.5 | 4.9 | 14.8 | 3.7 | |
Other Equity, Total | -8511.2 | -8845.3 | -8742.4 | -9541.7 | -9524.4 | -7360 |
Total Liabilities & Shareholders’ Equity | 38805.9 | 44981 | 43908.4 | 39286.1 | 46633.1 | 48806 |
Total Common Shares Outstanding | 1100.88 | 1100.01 | 1057.64 | 957.526 | 956.59 | 953.653 |
Other Current Assets, Total | 2229.1 | 0 | ||||
Deferred Income Tax | 1312.7 | 2187.5 | 2099.9 | 1733.7 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Käibevarad kokku | 16604.5 | 17295.5 | 17808.3 | 18452.4 | 16964.7 |
Raha ja lühiajalised investeeringud | 3051.4 | 3271.2 | 3825.3 | 3908.6 | 2568.3 |
Raha ja ekvivalendid | 3002.4 | 3220 | 3788.2 | 3818.5 | 2459.2 |
Lühiajalised investeeringud | 49 | 51.2 | 37.1 | 90.1 | 109.1 |
Laekumata arved, neto | 6658.6 | 6902.8 | 7025 | 8127.2 | 7805.7 |
Accounts Receivable - Trade, Net | 5592.8 | 5829.4 | 5914.3 | 6672.8 | 6322.5 |
Total Inventory | 3660.8 | 3824.9 | 3907.4 | 3886 | 3893 |
Prepaid Expenses | 3233.7 | 3296.6 | 3050.6 | 2530.6 | 2697.7 |
Total Assets | 46838.3 | 47809 | 48187 | 48806 | 46919.3 |
Property/Plant/Equipment, Total - Net | 8630.1 | 8855.5 | 8920.4 | 8985.1 | 9102.7 |
Property/Plant/Equipment, Total - Gross | 18273.5 | 18697.7 | 18883.2 | 18961.8 | 19241 |
Accumulated Depreciation, Total | -9643.4 | -9842.2 | -9962.8 | -9976.7 | -10138.3 |
Goodwill, Net | 3877.4 | 3884.2 | 3884.1 | 3892 | 3892 |
Intangibles, Net | 8087.8 | 7985.4 | 7887.7 | 7691.9 | 7482.4 |
Long Term Investments | 3232.4 | 3474.9 | 3350.5 | 3212.6 | 2727.3 |
Other Long Term Assets, Total | 6406.1 | 6313.5 | 6336 | 6572 | 6750.2 |
Total Current Liabilities | 11714.2 | 15093.2 | 13682 | 15052.7 | 13386 |
Accounts Payable | 1639.6 | 1597.8 | 1566.8 | 1670.6 | 1433.3 |
Accrued Expenses | 649.9 | 755.5 | 836.6 | 958.1 | 693.1 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 4.9 | 1778.5 | 1563 | 1538.3 | 1355.9 |
Other Current Liabilities, Total | 9419.8 | 10961.4 | 9715.6 | 10885.7 | 9903.7 |
Total Liabilities | 39939.6 | 41364.6 | 40430 | 39826.8 | 37588.5 |
Total Long Term Debt | 16199.6 | 14736.6 | 15522.4 | 15346.4 | 15152.9 |
Long Term Debt | 16199.6 | 14736.6 | 15522.4 | 15346.4 | 15152.9 |
Deferred Income Tax | 2200.6 | 1857.3 | 1632.5 | 1733.7 | 1286.1 |
Minority Interest | 200.6 | 219.1 | 197.1 | 175.6 | 131.2 |
Other Liabilities, Total | 9624.6 | 9458.4 | 9396 | 7518.4 | 7632.3 |
Total Equity | 6898.7 | 6444.4 | 7757 | 8979.2 | 9330.8 |
Common Stock | 599.7 | 598.1 | 598.2 | 596.3 | 594.1 |
Additional Paid-In Capital | 6579.2 | 6669.2 | 6758 | 6833.4 | 6656.3 |
Retained Earnings (Accumulated Deficit) | 9181.3 | 8530.1 | 9639.4 | 8958.5 | 9369.4 |
Treasury Stock - Common | -52.7 | -52.7 | -52.7 | -52.7 | -50.5 |
Unrealized Gain (Loss) | 4.5 | 9.1 | 6.8 | 3.7 | -18.1 |
Other Equity, Total | -9413.3 | -9309.4 | -9192.7 | -7360 | -7220.4 |
Total Liabilities & Shareholders’ Equity | 46838.3 | 47809 | 48187 | 48806 | 46919.3 |
Total Common Shares Outstanding | 959.019 | 956.575 | 956.589 | 953.653 | 950.155 |
- Aastas
- Kvartalis
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Netotulu/algväärtus | 2737.6 | -204.1 | 3232 | 8318.4 | 6193.7 | 5581.7 |
Raha majandustegevusest | 4851 | 5615.6 | 5524.5 | 4836.6 | 6499.6 | 7260.7 |
Raha majandustegevusest | 1496.6 | 1567.3 | 1609 | 1232.6 | 1323.9 | 1547.6 |
Deferred Taxes | 439.5 | -787.9 | 326.8 | 62.4 | -134.5 | -802.3 |
Mittelikviidsed varad | 661.4 | 1835.4 | 2735.4 | -3089.6 | -136.1 | 1956.3 |
Cash Taxes Paid | 700.6 | 246.5 | 1101.5 | 1180.5 | 954.6 | 1598.8 |
Makstud intressid | 146.4 | 192.7 | 223.8 | 305.5 | 345.8 | 338 |
Muutused tööjõus | -484.1 | 3204.9 | -2378.7 | -1687.2 | -747.4 | -1022.6 |
Tulu investeeringutelt | -3139.1 | -3783.6 | 1906 | -8082.9 | -2258.9 | -2762.3 |
Kapitalikulutused | -1092 | -2163.6 | -3018.2 | -1353.5 | -2029.1 | -1873.2 |
Muud rahavood investeeringutelt, kokku | -2047.1 | -1620 | 4924.2 | -6729.4 | -229.8 | -889.1 |
Rahavood investeeringutelt | -559.8 | 142.6 | -5904.9 | -2324.5 | -3137.1 | -4131.3 |
Rahavoogudesse investeerimine | -300.8 | -364.4 | -372.8 | -200.1 | -241.6 | -295.9 |
Total Cash Dividends Paid | -2158.5 | -2192.1 | -2311.8 | -2409.8 | -2687.1 | -3086.8 |
Aktsiate emiteerimine (tagasiost), neto | -600.1 | -299.8 | -2491 | -4400 | -500 | -1250 |
Laenu väljastamine (kustutamine), neto | 2499.6 | 2998.9 | -729.3 | 4685.4 | 291.6 | 501.4 |
Muutused valuutakursside kõikumisest | -236.4 | -20.5 | -63.6 | -89.9 | 216 | -205.7 |
Rahaline kogumuutus | 915.7 | 1954.1 | 1462 | -5660.7 | 1319.6 | 161.4 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 1355.3 | 2745.5 | 3855.6 | 5581.7 | 1902.9 |
Cash From Operating Activities | 1697.4 | 3472.9 | 5104.2 | 7260.7 | 2499.2 |
Cash From Operating Activities | 350.3 | 719.6 | 1101.9 | 1547.6 | 435.7 |
Deferred Taxes | -119.1 | -413.8 | -709.8 | -802.3 | -506.6 |
Non-Cash Items | 213.7 | 303.2 | 1404.6 | 1956.3 | 712.7 |
Changes in Working Capital | -102.8 | 118.4 | -548.1 | -1022.6 | -45.5 |
Cash From Investing Activities | -1283.5 | -1766.8 | -2383.3 | -2762.3 | -1013.8 |
Capital Expenditures | -492.1 | -1023.4 | -1479 | -1873.2 | -857.2 |
Other Investing Cash Flow Items, Total | -791.4 | -743.4 | -904.3 | -889.1 | -156.6 |
Cash From Financing Activities | -1058.4 | -2141.6 | -2604.8 | -4131.3 | -2878.3 |
Financing Cash Flow Items | -279.9 | -294.8 | -295.3 | -295.9 | -282.4 |
Total Cash Dividends Paid | -774.8 | -1543.1 | -2313.5 | -3086.8 | -885.5 |
Issuance (Retirement) of Stock, Net | 0 | -500 | -500 | -1250 | -1500 |
Issuance (Retirement) of Debt, Net | -3.7 | 196.3 | 504 | 501.4 | -210.4 |
Foreign Exchange Effects | -10.2 | -1.6 | 15 | -205.7 | 33.6 |
Net Change in Cash | -654.7 | -437.1 | 131.1 | 161.4 | -1359.3 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
Lilly Endowment, Inc. | Investment Advisor | 10.8347 | 102948810 | -210000 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 7.6008 | 72221213 | 994066 | 2022-09-30 | LOW |
PNC Wealth Management | Investment Advisor | 5.4451 | 51738161 | -44061 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.2364 | 40253792 | 58949 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.5343 | 33582472 | 168444 | 2022-09-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 3.3604 | 31929656 | 631015 | 2022-09-30 | LOW |
Capital World Investors | Investment Advisor | 3.0547 | 29024874 | 282228 | 2022-09-30 | LOW |
PRIMECAP Management Company | Investment Advisor | 2.9486 | 28017155 | -421333 | 2022-09-30 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.5054 | 23805927 | 3379269 | 2022-09-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 2.2989 | 21843288 | -1593968 | 2022-09-30 | LOW |
State Farm Insurance Companies | Insurance Company | 1.8324 | 17410725 | 0 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.6935 | 16091249 | 373938 | 2022-09-30 | LOW |
Jennison Associates LLC | Investment Advisor/Hedge Fund | 1.0592 | 10064742 | -293324 | 2022-09-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 0.866 | 8228610 | 173535 | 2022-09-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.8435 | 8014500 | -246196 | 2021-12-31 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7439 | 7068030 | -132558 | 2022-09-30 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.6244 | 5933104 | -307204 | 2022-09-30 | LOW |
Capital International Investors | Investment Advisor | 0.5893 | 5599174 | 637189 | 2022-09-30 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.5885 | 5591703 | -216451 | 2022-09-30 | LOW |
BofA Global Research (US) | Research Firm | 0.5868 | 5576096 | -144521 | 2022-09-30 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com GroupKauplejad
Igakuiste aktiivsete klientide arv
Igakuine investeerimise maht
Igakuiselt välja võetud
Kauplemiskalkulaator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Eli Lilly Company profile
Ettevõttest Eli Lilly & Co
Eli Lilly and Company on ravimit tootev ettevõte. Ettevõte tegeleb farmaatsiatoodete väljatöötamise, arendamise, tootmise, turustamise ja müügiga kogu maailmas. Ettevõtte diabeeditoodete hulka kuuluvad Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta ja Trulicity. Ettevõtte onkoloogiatoodete hulka kuuluvad Alimta, Cyramza, Erbitux, Retevmo, Tyvyt ja Verzenio. Ettevõtte immunoloogiatoodete hulka kuuluvad Olumiant ja Taltz. Tema neuroteaduslike toodete hulka kuuluvad Cymbalta, Emgality, Reyvow ja Zyprexa. Muude ravimeetodite hulka kuuluvad Bamlanivimab, etesevimab, Cialis ja Forteo. Ettevõte toodab ja turustab oma tooteid Ameerika Ühendriikides, sealhulgas Puerto Ricos, ja veel umbes kaheksas riigis asuvate rajatiste kaudu. Ettevõtte tooteid müüakse ligikaudu 120 riigis. Ettevõtte tütarettevõtete hulka kuuluvad muu hulgas Acanthas Pharma, Inc., Alnara Pharmaceuticals, Inc., ARMO Biosciences, Inc. ja Avid Radiopharmaceuticals, Inc.
Industry: | Pharmaceuticals (NEC) |
Lilly Corporate Ctr
Drop Code 1094
INDIANAPOLIS
INDIANA 46285-0001
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 485,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com